MUC1 and breast cancer: In a pilot clinical trial of oxidized mannan–MUC-1 (M-FP) for the treatment of patients with stage II BC, the follow-up at 12-15 years showed that the recurrence rate was 12.5% (2/16) in the vaccine group compared with 60% (9/15) in the placebo group.